- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00399204
Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients
March 18, 2019 updated by: SHotra, Postgraduate Institute of Medical Education and Research
A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes
The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chandigarh, India, 160012
- PGIMER
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years.
- Ready to give written informed consent
Exclusion Criteria:
- Presence of ketonuria
- Severe concurrent, infection or illness
- History of hypersensitivity to any study drug
- Impaired renal function
- Pulmonary insufficiency with hypoxemia
- Severe hepatic disease
- Congestive heart failure
- History of myocardial infarction or angina(stable/unstable)
- History of alcohol or drug abuse
- Pregnant or lactating women -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Metformin
|
|
Experimental: Experimental
Pioglitazone
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Promila Pandhi, Postgraduate Institute of Medical Education and Research
- Principal Investigator: Nusrat Shafiq, MD,DM, Postgraduate Institute of Medical Education and Research
- Study Director: Anil Bhansali, MD,DM, Postgraduate Institute of Medical Education and Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2006
Primary Completion (Anticipated)
December 1, 2012
Study Completion (Anticipated)
December 1, 2012
Study Registration Dates
First Submitted
November 13, 2006
First Submitted That Met QC Criteria
November 13, 2006
First Posted (Estimate)
November 14, 2006
Study Record Updates
Last Update Posted (Actual)
March 20, 2019
Last Update Submitted That Met QC Criteria
March 18, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pharma6/701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Pioglitazone vs Metformin
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
University of MinnesotaNot yet recruitingOral LeukoplakiaUnited States
-
Huazhong University of Science and TechnologyHubei Xinhua Hospital; Wuhan Iron and Steel Workers' Hospital; Wuhan Pu-Ai HospitalCompletedDiabetes Mellitus, Type 2China
-
King Edward Medical UniversityCompleted
-
Khyber Medical University PeshawarCompletedPolycystic Ovarian SyndromePakistan
-
Daiichi Sankyo, Inc.CompletedDiabetes Mellitus, Type 2United States
-
Xiang Guang-daCompletedEndothelial Function | LVM | Type 2 Diabetic Patients With IHDChina
-
Dow University of Health SciencesUnknownHyperandrogenism | Menstrual IrregularitiesPakistan
-
Bing HeActive, not recruitingPolycystic Ovary SyndromeChina
-
Sun Yat-sen UniversityUnknownType 2 Diabetes MellitusChina